DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rlq98w/china_diabetes) has announced the addition of the "China Diabetes Market Outlook 2018" report to their offering.
Approximately 92 Million people in China had diabetes in 2012 and the number is estimated to reach approximately 130 Million by 2030. The country's diabetic population is rapidly growing owing to factors including growing ageing population, rising obesity rates and increasing westernization. Not only this, the country has a significant share in the diabetes market globally. Chinese government authorities are spending a huge amount of money on diabetics. The growth in diabetes drug spending in the country is currently running at 11% and is estimated to reach approximately US$ 4.6 Billion by 2018.
In this latest report China Diabetes Market Outlook 2018, the country's diabetes market has been segmented into oral drugs, insulin drugs, insulin delivery devices and self-monitoring glucose monitoring devices. The authors have identified the growth potential of diabetes with respect to each of these segments thereby highlighting the potential for market players. The report also highlights the healthcare expenditures pertaining to diabetes treatment in the country which will help clients in understanding the future demand scenario.
The report provides an exhaustive overview of the technological developments for insulin delivery devices and glucose monitoring systems which would help the client understand various advanced technology systems available in the market. The overall study analyses the current and future outlook of diabetes drugs as well as insulin delivery device systems in China.
The report covers the major drivers and trends impacting the China diabetes market. It provides an insight into strategic activities by major market players. Several companies have been trying to tap the potential market demand for diabetes treatment. However, market players have been extending their product portfolios in order to gain their own market shares.
The authors conclude with a competitive analysis of major market players providing their business overviews specific to the China diabetes market along with their product portfolios. It also elucidates the key developments of the players pertaining to this market and provides an overview of the regulatory environment for diabetes and patient profile that will help clients in formulating market strategies and in assessing opportunity areas in the China diabetes market.
Key Topics Covered:
Analyst View
Research Methodology
Patient Profile Analysis
Cost Implications
Market Drivers and Trends
Diabetes Drugs Market
Insulin Delivery Devices Market
Glucose Monitoring Devices Market
Government Regulations and Initiatives
Key Players
List of Charts
Companies Mentioned
- Bayer
- Eli Lilly
- Medtronic
- Merck & Co.
- Novo Nordisk
- Sanofi-Aventis
- Terumo Corporation
- Tianjin Takeda Pharmaceuticals Co Ltd.
- Tonghua Dongbao Pharmaceutical Co. Ltd.
For more information visit http://www.researchandmarkets.com/research/rlq98w/china_diabetes
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
